Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to $4.1 million.

  • CorMedix's Share-based Compensation rose 23121.14% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 12857.77%. This contributed to the annual value of $6.1 million for FY2024, which is 1157.05% up from last year.
  • Per CorMedix's latest filing, its Share-based Compensation stood at $4.1 million for Q3 2025, which was up 23121.14% from $2.7 million recorded in Q2 2025.
  • CorMedix's Share-based Compensation's 5-year high stood at $4.1 million during Q3 2025, with a 5-year trough of $50000.0 in Q2 2022.
  • Over the past 5 years, CorMedix's median Share-based Compensation value was $1.2 million (recorded in 2024), while the average stood at $1.6 million.
  • Per our database at Business Quant, CorMedix's Share-based Compensation plummeted by 9504.98% in 2022 and then soared by 175859.56% in 2024.
  • CorMedix's Share-based Compensation (Quarter) stood at $1.3 million in 2021, then crashed by 30.26% to $874051.0 in 2022, then crashed by 92.22% to $68000.0 in 2023, then surged by 1655.75% to $1.2 million in 2024, then soared by 240.52% to $4.1 million in 2025.
  • Its last three reported values are $4.1 million in Q3 2025, $2.7 million for Q2 2025, and $3.5 million during Q1 2025.